About This Article
To assess the efficacy, safety and pharmacokinetic/pharmacodynamic properties of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D).
![Pharmacokinetic and Dose-Finding Studies on Efpeglenatide in Patients With Type 2 Diabetes thumbnail](https://prosciento.com/wp-content/uploads/2022/01/journal-7.png)
To assess the efficacy, safety and pharmacokinetic/pharmacodynamic properties of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D).